Anthony W. Tolcher

机构：Texas Oncology, Urology San Antonio, South Texas Accelerated Research Therapeutics · ORCID：0000-0002-6322-9721

发表论文 975 篇 · 总被引 24858 次 · h-index 76

代表论文

• Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer (2026 · New England Journal of Medicine · 被引 27)
• Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors (2026 · New England Journal of Medicine · 被引 24)
• A phase 1, first-in-human (FIH) study evaluating the safety, pharmacokinetics, and efficacy of ABBV-969 in patients with metastatic castration-resistant prostate cancer (mCRPC). (2026 · Journal of Clinical Oncology · 被引 3)
• Advancing Antibody-Drug Conjugates: Current Perspectives and Future Directions (2026 · American Society of Clinical Oncology Educational Book · 被引 2)
• Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors (2026 · Cancer Research Communications · 被引 1)
• Phase 1 evaluation of ASP3082, a first-in-class selective protein degrader, in patients (pts) with KRAS G12D -mutant pancreatic ductal adenocarcinoma (PDAC): Pharmacokinetics (PK) and biomarker insights. (2026 · Journal of Clinical Oncology · 被引 1)